Amorphous solid dispersions

CN116685308BActive Publication Date: 2026-11-17UCB BIOPHARMA SPRL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202180084509.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-12-18
Filing Date
2021-12-16
Publication Date
2026-11-17
Estimated Expiration
2041-12-16

AI Technical Summary

Technical Problem

[0010]2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1S,3R)-3-(羟甲基)-5-(1-羟基-1-甲基-乙基)-1-甲基-3,4-二氢-1H-异喹啉-2-基]乙酮的这种一水化晶型具有有限的溶解性,如果期望口服,则其可能导致其配制困难和/或低生物利用度

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116685308B_ABST
    Figure CN116685308B_ABST
Patent Text Reader

Abstract

This invention relates to amorphous compounds of formula (I) and solid dispersions of polymer matrices, methods for their preparation, and their use in therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Invention Field

[0001] This invention relates to a solid dispersion of amorphous 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone.

[0002] The present invention also relates to methods for preparing these amorphous solid dispersions and pharmaceutical compositions comprising such dispersions. Background of the Invention

[0004] International patent application n°PCT / EP2020 / 068183, published as WO2021 / 001288, discloses 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone of formula (I).

[0005]

[0006] This compound functions as a D1 orthoallosteric modulator, and therefore has potential benefits as a drug substance for treating diseases that affect the D1 receptor.

[0007] International patent application n°PCT / EP2020 / 068183, published as WO2021 / 001288, also discloses that compounds of formula (I) can be used to treat and / or prevent cognitive and negative symptoms in schizophrenia, cognitive impairment associated with psychiatric sedation therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain.

[0008] Therefore, it is desirable to develop formulations of compounds of formula (I) suitable for administration to patients suffering from any of the diseases mentioned above.

[0009] In particular, the monohydrated form of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone is specifically disclosed in Example 2.8 of International Patent Application No. PCT / EP2020 / 068183 published in WO2021 / 001288.

[0010] This monohydrated form of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone has limited solubility, which may lead to difficulties in formulation and / or low bioavailability if oral administration is desired.

[0011] Therefore, there is a need to improve the solubility of the monohydrated form of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone so that it can be incorporated into pharmaceutical compositions, particularly those intended for oral administration. Invention Overview

[0013] The present invention provides an amorphous solid dispersion of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone of formula (I).

[0014]

[0015] In another aspect, the present invention provides a method for preparing an amorphous solid dispersion of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone of formula (I).

[0016] In another aspect, the present invention provides a pharmaceutical composition comprising an amorphous solid dispersion of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone of formula (I).

[0017] In another aspect, the present invention provides such amorphous solid dispersions of formula (I) of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone, or pharmaceutical compositions thereof, for the treatment and / or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with sedative therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain.

[0018] Attached Figure Description

[0019] Figure 1 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD1 described in Example 3.1.

[0020] Figure 2 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD2 described in Example 3.1.

[0021] Figure 3 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD3 described in Example 3.1.

[0022] Figure 4 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD4 further described in Example 3.1.

[0023] Figure 5 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD1 described in Example 3 after 12 months at room temperature.

[0024] Figure 6 The X-ray powder diffraction patterns of the amorphous solid dispersions ASD2, ASD3 and ASD4 described in Example 3 after 10 months at room temperature are shown.

[0025] Figure 7 The dissolution curves of the amorphous solid dispersion ASD1 described in Example 5, which is transformed into the compound of formula (I), are shown as changes over time.

[0026] Figure 8The dissolution curves of the monohydrated form of 2-(3,5-dichloro-1-methyl-indazole-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone (the compound of formula (Ia)) as described in Example 5 are shown as a function of time.

[0027] Figure 9 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD5 further described in Example 3.2.

[0028] Figure 10 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD6 further described in Example 3.2.

[0029] Figure 11 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD7 further described in Example 3.2.

[0030] Figure 12 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD8 further described in Example 3.2.

[0031] Figure 13 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD9 further described in Example 3.2.

[0032] Figure 14 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD10 further described in Example 3.2.

[0033] Figure 15 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD11 further described in Example 3.2.

[0034] Figure 16 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD12 further described in Example 3.2.

[0035] Figure 17 The image shows the X-ray powder diffraction pattern of the amorphous solid dispersion ASD13 further described in Example 3.2.

[0036] Figure 18 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD14 further described in Example 3.2.

[0037] Figure 19 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD15 further described in Example 3.2.

[0038] Figure 20 The bioavailability of the compound of formula (I) is expressed as a function of the dosage of the ASD1 suspension prepared according to Example 6.1.

[0039] Figure 21 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD16 further described in Example 3.2.

[0040] Figure 22 This represents the X-ray powder diffraction pattern of the amorphous solid dispersion ASD17 further described in Example 3.2.

[0041] Figure 23 The dissolution curves show the changes over time of the compound of formula (I) in tablet A as described in Example 7.2.

[0042] Figure 24 The dissolution curves show the changes over time of the compound of formula (I) in tablet B as described in Example 7.2.

[0043] Figure 25 The dissolution curves show the changes over time of the compound of formula (I) in tablet C as described in Example 7.2.

[0044] Figure 26 The dissolution curves show the changes over time of the compound of formula (I) in tablet D as described in Example 7.2.

[0045] Figure 27 The X-ray powder diffraction patterns of tablet A are shown before and after storage for 12 months under the conditions described in Example 7.3.

[0046] Figure 28 The X-ray powder diffraction patterns of tablet B are shown before and after storage for 12 months under the conditions described in Example 7.3.

[0047] Figure 29 The X-ray powder diffraction patterns of tablet D are shown before and after storage for 12 months under the conditions described in Example 7.3. Invention Details

[0049] As used in this application, the term "amorphous solid dispersion" refers to a solid dispersion comprising an amorphous compound of formula (I) and a polymer matrix as defined in this application.

[0050] As used in this application, the term "solid dispersion" refers to a solid system comprising at least two components, one of which is dispersed throughout the other component.

[0051] As used in this application, "amorphous compound of formula (I)" means a compound of formula (I) that is substantially free of crystalline structures. The amorphous properties of solids are typically determined by X-ray powder diffraction (XRPD). The X-ray powder diffraction pattern of an amorphous solid typically represents a broad halo without sharp peaks, which will be apparent to those skilled in the art using conventional XRPD techniques.

[0052] "Substantially free of crystalline form" means that, with respect to the compound of formula (I), as measured by X-ray powder diffraction using conventional methods further described in this application, it contains at least 95%, suitably at least about 98%, ideally at least about 99% of the compound of formula (I) in its amorphous form.

[0053] As used in this application, the term "polymer matrix" refers to any polymer selected from the group consisting of: hydroxypropyl methyl cellulose acetate succinate (also known as HPCMAS), copolymer N-vinyl-2-pyrrolidone / vinyl acetate (also known as PPVVA), polyvinylpyrrolidone (also known as PVP), hydroxypropyl methyl phthalate (also known as HPMC), and hydroxypropyl methyl cellulose (also known as HPMC). As is evident from the experimental section, these polymer matrices are generally commercially available and can be obtained in different physical / chemical grades.

[0054] In a first aspect, the present invention provides a solid dispersion comprising an amorphous compound of formula (I) and hydroxypropyl methylcellulose acetate succinate.

[0055] In a second aspect, the present invention provides a solid dispersion comprising an amorphous compound of formula (I) and a copolymer N-vinyl-2-pyrrolidone / vinyl acetate.

[0056] In a third aspect, the present invention provides a solid dispersion comprising an amorphous compound of formula (I) and polyvinylpyrrolidone.

[0057] In a fourth aspect, the present invention provides a solid dispersion comprising an amorphous compound of formula (I) and hydroxypropyl methylcellulose phthalate.

[0058] In a fifth aspect, the present invention provides a solid dispersion comprising an amorphous compound of formula (I) and hydroxypropyl methylcellulose.

[0059] The amorphous solid dispersion according to the invention comprises about 30% to about 60% by weight of an amorphous compound of formula (I), referred to below as "wt%" in relation to the total weight of the amorphous solid dispersion.

[0060] In a first embodiment of the invention, the amorphous solid dispersion comprises about 30% by weight of an amorphous compound of formula (I).

[0061] In a second embodiment of the invention, the amorphous solid dispersion comprises about 40% by weight of an amorphous compound of formula (I).

[0062] In a third embodiment of the invention, the amorphous solid dispersion comprises about 50% by weight of an amorphous compound of formula (I).

[0063] In a fourth embodiment of the invention, the amorphous solid dispersion comprises about 60% by weight of an amorphous compound of formula (I).

[0064] Specific examples of amorphous solid dispersions according to the present invention include: an amorphous solid dispersion comprising about 30% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose acetate succinate; an amorphous solid dispersion comprising about 40% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose acetate succinate; an amorphous solid dispersion comprising about 50% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose acetate succinate; an amorphous solid dispersion comprising about 60% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose acetate succinate; an amorphous solid dispersion comprising about 40% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose; and an amorphous solid dispersion comprising about 50% by weight of a compound of formula (I) and hydroxypropyl methyl cellulose. Amorphous solid dispersions of the compound of formula (I) and hydroxypropyl methylcellulose; amorphous solid dispersions of the compound of formula (I) and hydroxypropyl methylcellulose phthalate comprising about 40% by weight; amorphous solid dispersions of the compound of formula (I) and hydroxypropyl methylcellulose phthalate comprising about 50% by weight; amorphous solid dispersions of the compound of formula (I) and polyvinylpyrrolidone comprising about 40% by weight; amorphous solid dispersions of the compound of formula (I) and polyvinylpyrrolidone comprising about 50% by weight; and amorphous solid dispersions of the compound of formula (I) and the copolymer N-vinyl-2-pyrrolidone / vinyl acetate comprising about 40% by weight.

[0065] For example, the amorphous solid dispersion according to the invention can be prepared by spray drying. Typically, a monohydrated crystal form of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone of a compound referred to below as formula (Ia) and a polymer matrix as defined in this application are dissolved in a suitable solvent or a mixture of suitable solvents to form a feed solution, which is then spray-dried into an amorphous solid dispersion in powder form. Spray drying is a method well known to those skilled in the art for preparing amorphous solid dispersions.

[0066] The spray drying method according to the invention is typically operated continuously and includes the following steps: (i) preparing a feed solution in which the compound of formula (Ia) and the carrier are dissolved in an organic solvent; (ii) conveying the feed solution to a drying chamber via an atomizer; (iii) contacting the droplets formed in step (ii) with a hot drying gas; (iv) evaporating the solvent; and (v) separating the dried solid particles from the drying gas.

[0067] Suitable solvents for use in the spray drying method according to the present invention are dichloromethane (DCM), methanol, ethanol, ethyl acetate, acetone, water, or mixtures thereof. Specifically, a mixture of dichloromethane and methanol is used according to the present invention, as further described in the examples.

[0068] Atomization is typically achieved through conventional methods, such as by feeding the solution through a nozzle at pressures ranging from about 0.5 bar to about 2.5 bar, ideally from about 1.00 bar to about 2.5 bar.

[0069] The hot drying gas used in the drying chamber can be selected from air, nitrogen-rich air, or argon. The temperature of the hot drying gas typically ranges from about 50°C to about 120°C, preferably from about 60°C to 120°C, such that the outlet temperature ranges from about 40°C to about 65°C.

[0070] The solid particles obtained after step (v) can be further dried by conventional means at a temperature of about 25°C to about 50°C under atmospheric or reduced pressure.

[0071] Alternatively, amorphous solid dispersions can be prepared by methods including hot melt extrusion. Hot melt extrusion methods typically include: i) feeding a system containing the extruded material in a continuous flow or in a controlled manner, in this invention, a powder mixture of a compound of formula (Ia) and a polymer matrix; ii) a conveying component made of a barrel and screw, designed to transport, melt, and homogenize the fed blend; iii) shaping the melt into a desired form, including sheets, films, or wires, using a die; iv) other steps in downstream processes, including cooling, possibly granulation or grinding, and collecting the resulting amorphous solid dispersion.

[0072] Hot melt extrusion is typically carried out at barrel temperatures above 100°C, and appropriately at temperatures above 150°C.

[0073] Therefore, in another aspect, the present invention provides a method for preparing an amorphous solid dispersion of compound (I) by spray drying or hot melt extrusion.

[0074] As described above and in the examples, it has been passed Figure 1-4 The XRPD shown in 9-19 characterizes the amorphous solid dispersion of the present invention.

[0075] Furthermore, the glass transition temperature (Tg) of the amorphous solid dispersion according to the invention was measured by modulated differential scanning calorimetry according to methods conventional to those skilled in the art, and is further described in Table 3 of the examples. Tg is considered to be the temperature at which an amorphous solid undergoes a distinct transition from a glassy solid to a supercooled liquid upon heating (see A. Newman and G. Zografi in AAPS PharmSciTech (2020) 21:26). Tg provides an indicator of the miscibility of the amorphous compound of formula (I) with the polymer matrix. If a single Tg or a narrow Tg region is measured, this indicates that the amorphous solid dispersion is homogeneous. This state is also referred to as a glass solution. Furthermore, the higher the Tg, the greater the likelihood that the amorphous solid dispersion will have reduced molecular mobility and therefore remain homogeneous over time; it is an indicator of its stability.

[0076] The amorphous solid dispersion according to the invention generally has a Tg greater than about 80°C, more generally greater than 100°C, suitably greater than about 105°C, ideally greater than about 110°C, suitably greater than about 115°C, and particularly greater than about 120°C.

[0077] The amorphous solid dispersions according to the invention generally have the measured Tg region explained above, which is below or equal to about 5°C.

[0078] Therefore, the amorphous solid dispersion according to the present invention is miscible and stable.

[0079] Furthermore, the stability over time of some amorphous solid dispersions according to the present invention has been tested at room temperature, and their properties are as follows: Figure 5 and Figure 6 The figures are shown and further described in detail in the embodiments. These figures show that these amorphous solid dispersions are stable at room temperature for at least 10 months.

[0080] The amorphous solid dispersion of the compound of formula (I) according to the invention is significantly more soluble than the monohydrated crystalline form of the compound of formula (I) (referred to herein as the compound of formula (Ia)). This improved solubility is particularly advantageous when pharmaceutical compositions are required, especially those for oral administration, as it allows for higher bioavailability. When solid dosage forms are desired, this also allows for reduced dosage and thus smaller tablet sizes.

[0081] Table 4 of the examples shows comparative solubility data between ASD1-ASD4 and the compound of formula (Ia) in different media, which shows that the solubility of the amorphous solid dispersions increases by at least 30 times and at most more than 100 times.

[0082] The amorphous solid dispersions according to the invention can also be combined with pharmaceutically acceptable excipients such as diluents, binders, disintegrants, lubricants, flow aids or carriers to form suitable pharmaceutical compositions.

[0083] Pharmaceutical compositions comprising the amorphous solid dispersion according to the invention can be administered, for example, orally, parenterally (i.e., intravenously, intramuscularly, or subcutaneously), intrathecally, by inhalation, or intranasally.

[0084] Suitable diluents and carriers can be available in a wide variety of forms, depending on the desired route of administration, such as oral, rectal, parenteral, or intranasal.

[0085] The pharmaceutical composition suitable for oral administration can be solid or liquid, and can be, for example, in the form of tablets, pills, sugar tablets, gelatin capsules, solutions, syrups, chewing gum, etc.

[0086] Pharmaceutical compositions according to the present invention are generally prepared by mixing an amorphous solid dispersion with an inert diluent or a non-toxic, pharmaceutically acceptable carrier such as starch, lactose, mannitol, or dicalcium phosphate, according to conventional pharmaceutical compounding techniques known to those skilled in the art. Additionally, these pharmaceutical compositions may also contain binders such as microcrystalline cellulose, tragacanth gum, or gelatin; disintegrants such as croscarmellose sodium or crospovidone alginate; lubricants such as magnesium stearate; flow aids such as colloidal silica; sweeteners such as sucrose or saccharin; or colorants or flavoring agents such as menthol or methyl salicylate; and coating substances, such as… (I, II, AMB II, QX or EZ).

[0087] In one specific embodiment, as further detailed in the method steps described in Example 7.1, a pharmaceutical composition according to the invention is prepared by mixing any of the amorphous solid dispersions according to the invention with an excipient.

[0088] The amount of amorphous solid dispersion in a pharmaceutical composition can fall within a wide concentration range and depends on a variety of factors, such as the patient's sex, age, weight, and medical condition, as well as the method of administration. Therefore, the amount of amorphous solid dispersion for oral administration is generally from about 0.5% to about 85% by weight relative to the total weight of the composition, suitably from about 20% to about 60% by weight relative to the total weight of the composition.

[0089] In one specific embodiment, the present invention relates to a solid pharmaceutical composition comprising an amorphous solid dispersion comprising, by weight, about 20% to about 60% of the total weight of an uncoated tablet, and any of the excipients mentioned above.

[0090] In particular, the present invention relates to tablet compositions comprising:

[0091] Amorphous solid dispersion of about 20% to about 60% by weight;

[0092] Approximately 10% to approximately 50% by weight of lactose monohydrate;

[0093] Microcrystalline cellulose, approximately 10% to approximately 50% by weight;

[0094] About 1% to about 5% by weight of croscarmellose sodium;

[0095] About 0.1% to about 2% by weight of colloidal anhydrous silica; and

[0096] Magnesium stearate, approximately 0.1% to approximately 5% by weight;

[0097] Compared to the total weight of uncoated tablets.

[0098] These excipients are typically mixed with the amorphous solid dispersion via one or more blending phases and optionally a diluting phase, as further described in Example 7.1.

[0099] In one embodiment, the pharmaceutical composition comprises about 25% by weight of an amorphous solid dispersion. In another embodiment, the pharmaceutical composition comprises about 50% by weight of an amorphous solid dispersion.

[0100] In a first embodiment, the pharmaceutical composition comprises about 47.15% by weight of lactose monohydrate. In a second embodiment, the pharmaceutical composition comprises about 27.5% by weight of lactose monohydrate.

[0101] In a first embodiment, the pharmaceutical composition comprises about 25.95% by weight of microcrystalline cellulose. In a second embodiment, the pharmaceutical composition comprises about 18.7% by weight of microcrystalline cellulose.

[0102] In a first embodiment, the pharmaceutical composition comprises about 1.35% by weight of croscarmellose sodium. In a second embodiment, the pharmaceutical composition comprises about 2.7% by weight of croscarmellose sodium.

[0103] In a first embodiment, the pharmaceutical composition comprises about 0.25% by weight of colloidal anhydrous silica. In a second embodiment, the pharmaceutical composition comprises about 0.50% by weight of colloidal anhydrous silica.

[0104] In a first embodiment, the pharmaceutical composition comprises about 0.30% by weight of magnesium stearate. In a second embodiment, the pharmaceutical composition comprises about 0.60% by weight of magnesium stearate.

[0105] In one specific implementation, the amorphous solid dispersion is ASD1.

[0106] The present invention also contemplates compositions that can release the active substance in a controlled manner. Pharmaceutical compositions suitable for parenteral administration are in conventional forms, such as aqueous or oily solutions or suspensions typically contained in ampoules, disposable syringes, glass or plastic vials, or infusion containers.

[0107] In addition to amorphous solid dispersions, these solutions or suspensions may optionally contain sterile diluents such as water for injection, physiological saline, oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents, antimicrobial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulfite, defoamers, chelating agents such as ethylenediaminetetraacetic acid, buffers such as acetates, citrates or phosphates, and substances for adjusting permeability such as sodium chloride or dextrose, as well as thickeners such as hydroxypropyl cellulose (HPC-SSL), hydroxypropyl methylcellulose derivatives (HPMC), and final stabilizers such as PPVVA, PVP and polyvinyl alcohol (PVA).

[0108] These drug forms are prepared using methods typically employed by pharmacists.

[0109] International patent application n°PCT / EP2020 / 068183, published as WO2021 / 001288, describes compounds of formula (I) that can be used to treat diseases and / or conditions in which D1 receptors function, particularly cognitive and negative symptoms in schizophrenia, cognitive impairment associated with psychiatric sedation therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain.

[0110] Therefore, in another aspect, the present invention provides an amorphous solid dispersion or a pharmaceutical composition thereof as described in this application for the treatment and / or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment associated with sedative therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain.

[0111] In one specific aspect, the present invention provides an amorphous solid dispersion or a pharmaceutical composition thereof as defined above for the treatment of cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia.

[0112] The present invention also provides the use of the amorphous solid dispersion or pharmaceutical composition thereof as described in this application in the preparation of medicaments for the treatment and / or prevention of cognitive and negative symptoms of schizophrenia, cognitive impairment associated with sedative therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain.

[0113] In one particular aspect, the present invention provides the use of an amorphous solid dispersion or a pharmaceutical composition thereof as defined above in the preparation of a medicament for treating cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease or schizophrenia.

[0114] The present invention also provides a method for treating and / or preventing cognitive and negative symptoms in schizophrenia, cognitive impairment associated with psychiatric sedation therapy, mild cognitive impairment (MCI), impulsivity, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease drug addiction, sleep disorders, emotional blunting, traumatic spinal cord injury, or neuropathic pain, the method comprising administering to a patient in need of such treatment an effective amount of an amorphous solid dispersion or a pharmaceutical composition thereof as described in this application.

[0115] In one specific aspect, the present invention provides a method for treating and / or preventing cognitive and negative symptoms in Parkinson's disease and other movement disorders, Alzheimer's disease, or schizophrenia, the method comprising administering to a patient in need of such treatment an effective amount of an amorphous solid dispersion or a pharmaceutical composition thereof as described in this application. Example

[0116] Abbreviations / Recurring Reagents

[0117] ACN: Acetonitrile

[0118] Salt water: saturated sodium chloride aqueous solution

[0119] nBu: n-Butyl

[0120] tBu: tert-butyl

[0121] Microcrystalline cellulose: Avicel PH-105 & PH-200 (trade names)

[0122] Cross-linked carboxymethyl cellulose sodium: Ac-Di-Sol (trade name)

[0123] cAMP: Cyclic Adenosine Monophosphate

[0124] DCM: Dichloromethane

[0125] DMAP: 4-Dimethylaminopyridine

[0126] DMF: N,N-dimethylformamide

[0127] DMSO: Dimethyl sulfoxide

[0128] mDSC: Modulation Differential Scanning Calorimetry

[0129] ES + Electrospray positive ionization

[0130] Et: Ethyl

[0131] EtOH: Ethanol

[0132] Et2O: Diethyl ether

[0133] EtOAc: Ethyl acetate

[0134] h: hours

[0135] HPLC: High Performance Liquid Chromatography

[0136] HTRF: Uniform Time-Resolved Fluorescence

[0137] HPCMAS-L: Hydroxypropyl methylcellulose acetate succinate, Grade L

[0138] HPMCAS-M: Hydroxypropyl methylcellulose acetate succinate, Grade M

[0139] HPMC E3LV: Hydroxypropyl methylcellulose E3LV grade

[0140] HPMC 15LV: Hydroxypropyl methylcellulose grade 15LV (trade name Affinisol)

[0141] HPMC 100LV: Hydroxypropyl methylcellulose grade 100LV (trade name Affinisol)

[0142] HPMCP HP-55: Hydroxypropyl methylcellulose phthalate HP55 grade, lactose monohydrate: FlowLac 90 (trade name)

[0143] LCMS: Liquid Chromatography-Mass Spectrometry

[0144] Magnesium stearate: HyQual 2257 (trade name)

[0145] MeOH: Methanol

[0146] min.: minutes

[0147] NCS: N-chlorosuccinimide

[0148] NMR: Nuclear Magnetic Resonance

[0149] iPrOH: Isopropanol

[0150] PVPVA 64: Copolymer N-vinyl-2-pyrrolidone / vinyl acetate

[0151] PVP 17PF: Polyvinylpyrrolidone 17PF grade

[0152] rt: room temperature

[0153] SFC: Supercritical Fluid Chromatography

[0154] Colloidal anhydrous silica: Cab-O-Sil M-5P (trade name)

[0155] TEA: Triethylamine

[0156] THF: Tetrahydrofuran

[0157] TLC: Thin-layer chromatography

[0158] Tg: Glass transition temperature

[0159] XRPD: X-ray powder diffraction

[0160] The IUPAC name was determined using Biovia Draw 16.1.

[0161] 1. Analytical Methods

[0162] All reactions involving air- or moisture-sensitive reagents are carried out in a nitrogen or argon atmosphere using dry solvents and glassware. Commercial solvents and reagents are generally used without further purification, including anhydrous solvents where appropriate (typically from Aldrich Chemical Company's Sure-Seal). TM Products or AcroSeal from Acros Organics TM Generally, after the reaction, thin-layer chromatography, HPLC, or mass spectrometry analysis is performed according to conventional methods known to those skilled in the art.

[0163] Crude substances can be purified by normal phase chromatography, (acidic or basic) reversed phase chromatography, chiral separation, or recrystallization.

[0164] The product is typically vacuum dried before final analysis and biological testing.

[0165] All NMR spectra were obtained at 250 MHz, 300 MHz, 400 MHz, or 500 MHz.

[0166] The compounds were studied in DMSO-d6, CDCl3, or MeOH-d4 solutions at a probe temperature of 300 K and a concentration of 10 mg / mL. The instrument was locked to the deuterium signal of DMSO-d6, CDCl3, or CD3OD. Chemical shifts are given as a low field from TMS (tetramethylsilane) as an internal standard in ppm.

[0167] Preparation of the monohydrated form (Ia) of 2,2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone

[0168] The compound of formula (Ia) was prepared by applying the same synthetic method described in Example 2 of the co-examined international patent application WO 2021 / 001288, which is incorporated herein by reference.

[0169] The following recrystallization scheme was also used as an alternative to the recrystallization scheme disclosed in Section 2.8:

[0170] Recrystallization was performed by dissolving 5.00 g of the crude material in 240 ml of dimethyl sulfoxide (DMSO). The solution was heated to 40 °C and then filtered through a P3 sintered glass filter. The reactor and filter were rinsed with 35 ml of DMSO. The filtrate was transferred to a clean reactor and heated to 85 °C. 110 ml of water was slowly added over 30 minutes. Then, 250 mg of compound (Ia) (0.5% w / w, monohydrate form) was added to the reaction mixture. The mixture was stirred at 85 °C for 2 h30 while crystals precipitated from the solution, and then slowly cooled to 20 °C over 12 hours. The suspension was filtered, and the filter cake was washed several times with water, followed by washing with 150 ml of ethyl acetate. The filter cake was dried under vacuum at 50–60 °C. Compound (Ia) was given as 46.9 g of a grayish-white powder. Yield = 94%.

[0171] 1H NMR (400MHz, DMSO-d6) δ7.65(dd,J=9.0,2.2Hz,1H),7.52(dd,J=9.0,2.1Hz,1H),7.37(d dd,J=19.6,7.6,1.7Hz,1H),7.25–7.03(m,2H),5.30(q,J=6.5Hz,0.3H),5.16–4.99(m,1. 7H),4.99–4.84(m,0.7H),4.63–4.30(m,3.3H),4.17–3.93(m,4H),3.28(dt,J=10.5,5.1 Hz, 1.3H), 3.10–2.85 (m, 1.7H), 1.56 (dd, J=13.2, 6.9Hz, 6.7H), 1.24 (d, J=6.5Hz, 2.3H).

[0172] 3. Preparation and characterization of amorphous solid dispersions of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone

[0173] 3.1. Spray drying solution

[0174] Compound (Ia) and the support were dissolved in an organic solvent and spray-dried to obtain different solid dispersions as described in paragraph 3.1.a and Table 1 below. The polymer matrix used is generally commercially available and can be obtained in different grades of quality.

[0175] Different types of spray drying equipment can be used. The spray drying equipment used in this solution is ProCept4M8-TriX (ProCept, Belgium).

[0176] 3.1.a. Synthesis of amorphous solid dispersion 1 (ASD1)

[0177] Approximately 40 g of the compound of formula (Ia) and approximately 60 g of commercially available HPCMAS-L, representing a weight ratio of approximately 40 / 60 wt%, were completely dissolved in a mixture of dichloromethane and methanol at 76 / 24 wt%, achieving a total solids content of approximately 5% (w / w) in the solution. The feed solution was then pumped to a two-fluid nozzle at a rate of 18 g / min and atomized into fine droplets. The solvent was evaporated by a co-current drying gas stream set at an inlet temperature of 65 °C. Atomization and drying parameters were adjusted to achieve an outlet temperature of 40–45 °C. Once evaporated, the dried particles were then collected via a cyclone separator. The collected wet material was stored in a vacuum oven at 25°C for 12 hours to obtain approximately 85 g of the desired amorphous solid dispersion of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone, which was designated ASD1. Yield = approximately 85% (material collected after the second drying / material dissolved in the feed solution)%.

[0178] Other amorphous solid dispersions can be prepared in a similar manner using the amounts of compounds of formula (Ia) summarized in Table 1 below and the polymer matrix.

[0179] Table 1 Composition of ASD 2-4

[0180] ASD Weight of compound (Ia) polymer matrix polymer matrix weight % ASD2 ~30% HPCMAS-L ~70% ASD3 ~60% HPCMAS-L ~40% ASD4 ~40% PVPVA ~60%

[0181] 3.2. Hot melt extrusion scheme

[0182] A powder mixture of approximately 10 g of compound (Ia) and polymer matrix in the weight ratios mentioned in Table 2 was prepared. For example, when 40% by weight of (Ia) is shown, this represents approximately 4.0 g of compound (Ia) and approximately 6.0 g of polymer matrix.

[0183] The polymer matrix used is generally commercially available and can be obtained in different grades of quality. The compound (Ia) and the polymer matrix are mixed using a three-dimensional oscillation system. (WAB) Blend for 5 minutes. Then sieve the premix through a #25 mesh (~700 μm) sieve to remove lumps, and use... The system was remixed for 5 minutes. The premixed powder was then manually fed into a lab-scale hot melt extruder (Thermo Scientific HAAKE™ MiniCTW Micro-Conical Twin Screw Compounder, ThermoFisher) operated with a counter-rotating screw configuration. The barrel temperature was fixed at 160°C, and the screw speed was limited to 200 rpm. A pressurized feeder was used to fill the barrel, with the screw feeder speed fixed at 500 rpm. The extrudate was collected after cooling to ambient temperature. Each extrudate was visually inspected after a single pass in the barrel. If the extrudate appeared opaque, the material was recirculated in the barrel for 2 minutes and extruded again. After extrusion, the material was ground for 1–2 minutes using a small-burr type grinding system while passing through a #60 mesh (~250 μm) sieve. The ground extrudate was sieved through a 250 μm sieve, and the different fractions were stored separately.

[0184]

[0185] 3.3. X-ray powder diffraction (XRPD) of ASD1-ASD17

[0186] The amorphous solid dispersions ASD1-ASD17 obtained by spray drying and hot melt extrusion as described in this application were characterized by XRPD according to the following general scheme.

[0187] X-ray powder patterns for ASD1–ASD15 were obtained using a PANalytical Empyrean Serie 2 X-ray powder diffractometer employing Cu Kα radiation and equipped with a Bragg-Brentano HD optical module with curved geometry for the incident beam path, and a PIXel 3D detector. Data was recorded using data acquisition software. During measurements, the tube voltage and current intensity were set to 45 kV and 40 mA, respectively. Samples placed in flat zero-background, zero-background cups, or post-loaded sample holders were analyzed at scan rates ranging from 0.2 to 2.1 ° / min between 4.5 and 30°2-θ. Data were processed using Data Viewer or HighScore Plus.

[0188] X-ray powder patterns for ASD16 and ASD17 were obtained using a Rigaku Miniflex 6G X-ray diffractometer employing Cu Kα radiation with a curved geometry. During measurements, the tube voltage and ampere were set to 40 kV and 15 mA, respectively. Samples placed in zero-background or low-volume zero-background cups were analyzed at scan rates of 0.9° / min between 3°2θ and 30°2θ. Data were processed using Data Viewer or HighScore Plus.

[0189] Figure 1-4 Images 9-19, 21, and 22 show the XPRD patterns of ASD1-ASD17, which exhibit typical amorphous solid-state halos. Note that the peaks appearing in the patterns of ASD7 and ASD12 are not attributed to the presence of the crystal form of the compound of formula (I), but rather to some impurities from the polymer matrix.

[0190] 3.4. Differential scanning calorimetry (DSC) determination of amorphous solid dispersions of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl]acetone

[0191] The phase behavior and thermal properties of ASD1-15 obtained in sections 3.1 and 3.2 were analyzed by modulated DSC (mDSC) using a TA Instruments Q1000 calorimeter (TA Instruments, Leatherhead, UK). The chamber was purged with dry nitrogen at a flow rate of 50 mL / min. Temperature / enthalpy and heat capacity were calibrated using indium and sapphire disks, respectively. The powder was analyzed in an unsealed standard aluminum disk (TA Instruments, Leatherhead, UK). In a typical mDSC analysis, the sample was heated from 0 °C to 250 °C at a rate of 2 °C / min, adjusted to ±1 °C, for a duration of 40–60 seconds. The data were processed using Universal Analysis 2000 software (TA Instruments, Leatherhead, UK). The glass transition temperature (Tg) is reported as the inflection point of the step change observed in the reverse heat flow signal, while crystallization and melting events were recorded in both the non-reverse and total heat flows.

[0192] Table 3 provides an overview of the Tg values ​​obtained for ASD1-ASD17.

[0193] ASD Tg(mDSC) ASD1 108-112℃ ASD2 105-110℃ ASD3 110-115℃ ASD4 120-125℃ ASD5 105-110℃ ASD6 105-110℃ ASD7 108-112℃ ASD8 110-115℃ ASD9 115-120℃ ASD10 135-140℃ ASD11 100-105℃ ASD12 105-110℃ ASD13 108-112℃ ASD14 110-115℃ ASD15 130-135℃ ASD16 83-87℃ ASD17 83-87℃

[0194] 3.5. Stability of ASD1, ASD2, ASD3 and ASD4

[0195] At t=0, it was obtained Figure 1-4 The XRPDs for ASD1-ASD4 are shown in the image.

[0196] Additionally, XRPDs of ASD1 were obtained after 12 months at 25°C and 60% relative humidity, and the resulting patterns were displayed. Figure 5 middle.

[0197] XRPDs of ASD2, ASD3, and ASD4 were also obtained after 10 months at room temperature in the presence of silica gel as a desiccant, and the resulting patterns showed... Figure 6 middle.

[0198] These studies show that ASD1-ASD4 are all stable for at least 10 months.

[0199] 4. Comparative solubility of amorphous solid dispersions of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone with compounds of formula (Ia).

[0200] The solubility of compound (Ia) and ASD1 in different media was determined using the shake-flask method. An excess of solid (equivalent to a concentration of 5 mg / mL of compound (I)) was suspended in 5 mL of buffer / bio-related medium as described in Table 4 and incubated for 24 h at RT and 37 °C in sealed glass vials (10 mL) in a climate chamber equipped with a rotary mixer. Assuming solubility was achieved at 24 h, the suspension was filtered through a 0.45 μm multi-free filter (Merck Millipore) and the drug concentration was determined by HPLC. The solubility of compound (Ia) and ASD1 was determined in triplicate (n = 3). If drug precipitation was required, the filtrate was diluted with a suitable organic solvent. Table 4 below shows the solubility of compound (Ia) compared to ASD1 in different media. These media are phosphate buffer, FasSGF, FASSIF-V2, and FeSSIF-V2, respectively. FasSG is gastric juice obtained after fasting. FasSGF was prepared at pH 1.6, containing 0.08 mM taurine, 0.02 mM phospholipid, 34 mM sodium, and 59 mM chloride. FaSSIF-V2 and FeSSIF-V2 were biorelevant mediators for fasted and fed states, respectively. FaSSIF-V2 was prepared at pH 6.5, containing 3 mM taurine, 0.2 mM phospholipid, 106 mM sodium, 69 mM chloride, and 19 mM maleic acid. FeSSIF-V2 was prepared at pH 5.8, containing 10 mM taurine, 2 mM phospholipid, 0.8 mM oleate, 5 mM monooleate, 218 mM sodium, 125 mM chloride, and 55 mM maleic acid.

[0201] Table 4

[0202]

[0203] The results obtained above show that, compared with the compound of formula (Ia), a minimum 30-fold increase in the solubility of ASD1 was achieved, and at most a greater than 100-fold increase.

[0204] 5. Dissolution characteristics of ASD1 and compounds of formula (Ia)

[0205] 5.1. General Plan

[0206] Dissolution characteristics were determined at 37°C in a USP Type 2 dissolution apparatus (Distek 2100C dissolution apparatus). Dynamic dissolution tests consisted of initial dissolution in simulated gastric medium (0.1N HCl) for 30 minutes to achieve a concentration equivalent to 1 mg / mL of compound (I), followed by dissolution in FaSSIF-V2 for 180 minutes to achieve a concentration equivalent to 0.5 mg / mL of compound (I).

[0207] 5.2. ASD1 dissolution

[0208] 125 mg of ASD1 was weighed and placed in a 100 mL container. Then, 50 mL of simulated gastric medium (0.1 N HCl) was added to the container, and the impeller speed was fixed at 100 rpm. After 30 minutes, an equal volume (50 mL) of fasting-state bioassociated medium was added to the container to obtain the FaSSIF-V2 composition. Dissolution was performed in triplicate (n = 3). At each time point, the suspension was filtered through a 0.45 μm ultra-free filter (Merck Millipore), and the content of compound (I) was determined by HPLC. The filtrate was then diluted with a suitable organic solvent. The dissolution curve of ASD1 is shown below. Figure 7 As shown in the image.

[0209] 5.3. Dissolution characteristics of compound (Ia)

[0210] Figure 8 The dissolution characteristics of compound (Ia) were shown under conditions similar to those described above.

[0211] from Figure 7 and 8 The comparison suggests that, compared to the compound of formula (Ia), ASD1 dissolves rapidly in gastric medium and remains highly soluble for several hours, while the solubility of compound (Ia) in gastric medium decreases to a very low level within the same timeframe. In summary, ASD1 was found to generate and maintain supersaturation throughout the experimental period.

[0212] This confirms that the amorphous solid dispersions according to the invention, particularly ASD1, have improved solubility characteristics compared to compounds of formula (Ia), and therefore possess advantageous properties.

[0213] 6. In vivo bioavailability of ASD1 liquid suspension

[0214] 6.1. ASD1 liquid suspension

[0215] The formulation media used in the following suspension is a mixture of 1% (w / v) SSL grade hydroxypropyl cellulose, 10% (w / v) PPVVA, and 0.1% (w / v) antifoaming agent 1510US in a 50 mM citrate buffer solution at pH 3.0.

[0216] First, an aqueous solution of 50 mM citrate buffer at pH 3.0 was prepared. Second, SSL grade hydroxypropyl cellulose, PPVVA, and defoamer 1510 US were continuously dissolved in the freshly prepared citrate buffer and stirred (magnetically stirred) for 120 minutes.

[0217] Weigh 15.0 g of ASD1 and place it in a container. Add 88.8 g of the prepared mediator to the ASD1 while manually mixing using a glass rod or INOX spatula. Then add another 88.8 g of the mediator and stir the suspension at 250 rpm for 30 minutes. Unless constant stirring is maintained, stir the suspension again for 15 minutes using a magnetic rod / stirrer before administration to animals and throughout the administration process.

[0218] 6.2. Application and bioavailability determination

[0219] Four groups of two male and two female dogs were treated with ASD1 in a suspension prepared according to Example 6.1 at doses of 10, 25, and 75 mg / kg / day for 14 consecutive days.

[0220] Plasma samples were collected at different time points after administration on day 1 and day 14: 1 h, 2 h, 4 h, 7 h, 12 h and 24 h after administration.

[0221] The plasma concentration of compound (I) was quantified by LC / MS (liquid chromatography / mass spectrometry).

[0222] The area under the curve (AUC) for days 1 and 14 between 0 and 24 hours was calculated using the log-lin interpolation rule. 24 ). The AUC 24 Divide by the administered dose and plot as a function of dose, as shown below. Figure 20 As shown in the image.

[0223] Figure 20 The AUC of compound (I) is shown. 24 The bioavailability of ASD1 in the suspension was increased proportionally to the dose administered, thus indicating that the bioavailability of ASD1 in the suspension remained at the same level when the dose was increased from 10 mg / kg to 75 mg / kg.

[0224] 7. Tablets containing ASD

[0225] 7.1. Preparation and composition of tablets containing amorphous solid dispersions

[0226] The amorphous solid dispersion obtained according to Example 3 was formulated into tablets according to the general process steps described below and in accordance with methods generally known to those skilled in the art:

[0227] 1) Blend the amorphous solid dispersion with suitable excipients such as microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, anhydrous colloidal silica and magnesium stearate;

[0228] 2) The blend obtained in step 1, referred to here as blend #1, is compacted by dry granulation and then ground;

[0229] 3) The particles obtained in step 2 are further blended with suitable excipients such as microcrystalline cellulose, croscarmellose sodium cellulose and magnesium stearate;

[0230] 4) After optionally diluting with microcrystalline cellulose and lactose monohydrate to a specific dose strength, the mixture, referred to below as blend #2, obtained as a result of step 3, is compressed to obtain an uncoated tablet.

[0231] 5) Use a suitable coating material, such as (I, II, AMB II, QX or EZ) Spray coating of the uncoated tablets.

[0232] Examples of tablets obtained by applying the above-mentioned process steps to ASD1 are as follows:

[0233] tablet A(mg) B(mg) C(mg) D(mg) Total weight of uncoated tablets 100 100 250 500 Step 1 - Blend #1 ASD 1mg 25.00 50 125 250 Lactose monohydrate 13.75 27.50 68.75 137.50 microcrystalline cellulose 6.85 13.70 34.25 68.50 Cross-linked carboxymethyl cellulose sodium 1.00 2.00 5.00 10.00 Colloidal anhydrous silica 0.25 0.50 1.25 2.50 magnesium stearate 0.15 0.30 0.75 1.50 Step 3 - Blend #2 microcrystalline cellulose 2.50 5.00 12.50 25.00 Cross-linked carboxymethyl cellulose sodium 0.35 0.70 1.75 3.50 magnesium stearate 0.15 0.30 0.75 1.50 Step 4 Lactose monohydrate 33.40 / / / microcrystalline cellulose 16.60 / / /

[0234] Coated tablets A, B, C, and D also contain approximately 4, 4, 10, and 20 mg of Opadry AMB II 88A180040 White, respectively.

[0235] 7.2. Dissolution characteristics of tablets A, B, C and D

[0236] The dissolution characteristics of coated tablets A, B, C & D were determined according to the scheme described in Example 5, and their dissolution characteristics are as follows: Figure 23 , 24 As shown in Figures 25 and 26. Note that the number of tablets or the volume of the dissolution medium can be adjusted to achieve the desired target concentration.

[0237] Results obtained using tablets A, B, C, and D show that amorphous solid dispersions and their corresponding solid formulations are advantageous in terms of solubility and dissolution rate compared to the monohydrated crystalline compounds of formula (Ia).

[0238] 7.3. Stability of tablets A, B, C, and D

[0239] Coated tablets A, B, and D, packaged in high-density polyethylene bottles (with 2g of silica gel desiccant embedded in the unscrewed cap), were found to be stable after 12 months of storage at 25°C and 60% relative humidity.

[0240] Figure 27 , Figure 28and Figure 29 The X-ray powder diffraction patterns of tablets A, B, and D before and after 12 months of storage under the conditions mentioned above are shown.

Claims

1. A solid dispersion of amorphous (I) 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] acetone and a polymer matrix. 。 2. The solid dispersion according to claim 1, wherein the polymer matrix is ​​selected from hydroxypropyl methylcellulose acetate, copolymer N-vinyl-2-pyrrolidone / vinyl acetate, polyvinylpyrrolidone, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose.

3. The solid dispersion according to claim 2, wherein the polymer matrix is ​​hydroxypropyl methylcellulose acetate or the copolymer N-vinyl-2-pyrrolidone / vinyl acetate.

4. The solid dispersion according to claim 1, comprising 30% to 60% by weight of an amorphous compound of formula (I) relative to the total weight of the amorphous solid dispersion.

5. The solid dispersion according to claim 4, comprising 40% by weight of an amorphous compound of formula (I) relative to the total weight of the amorphous solid dispersion.

6. The solid dispersion according to claim 1, having a glass transition temperature greater than 80°C.

7. The solid dispersion according to claim 6, having a glass transition temperature greater than 100°C.

8. A method for preparing the solid dispersion according to claim 2 by spray drying, the method comprising the following steps: (i) The monohydrated crystal form of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone and hydroxypropyl methylcellulose acetate, copolymer N-vinyl-2-pyrrolidone / vinyl acetate, polyvinylpyrrolidone, hydroxypropyl methylcellulose phthalate or hydroxypropyl methylcellulose are dissolved in a solvent. (ii) The solution obtained as a result of step (i) is transferred to the atomization chamber; (iii) Contact the droplets formed as a result of step (ii) with the hot, dry gas; (iv) Evaporate the solvent; (v) Separate the obtained solid dispersion from the dry gas.

9. A method for preparing the solid dispersion according to claim 2 by hot melt extrusion, the method comprising the following steps: (i) Mixing the monohydrated form of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinoline-2-yl] ethyl ketone with hydroxypropyl methylcellulose acetate, copolymer N-vinyl-2-pyrrolidone / vinyl acetate, polyvinylpyrrolidone, hydroxypropyl methylcellulose phthalate or hydroxypropyl methylcellulose; (ii) The mixture obtained in step (i) is fed into a hot melt extruder, wherein the mixture is continuously conveyed at a temperature greater than 150°C until a melt is obtained; (iii) The melt obtained in step (ii) of cooling at ambient temperature.

10. A pharmaceutical composition comprising a solid dispersion according to any one of claims 1 to 7 in combination with one or more pharmaceutically acceptable excipients.

11. A pharmaceutical composition comprising the solid dispersion according to claim 1, the pharmaceutical composition comprising a tablet comprising: Amorphous solid dispersions comprising 20% ​​to 60% by weight; 10% to 50% by weight of lactose monohydrate; 10% to 50% by weight of microcrystalline cellulose; 1% to 5% by weight of croscarmellose sodium; 0.1% to 2% by weight of colloidal anhydrous silica; and 0.1% to 5% by weight of magnesium stearate; Compared to the total weight of uncoated tablets.

12. Use of the solid dispersion according to any one of claims 1-7 or the pharmaceutical composition according to claim 10 or 11 in the preparation of a medicament for the treatment and / or prevention of the following conditions: cognitive symptoms and negative symptoms in schizophrenia, cognitive impairment associated with sedation therapy, mild cognitive impairment, impulsivity, attention deficit hyperactivity disorder, Parkinson's disease, dystonic disorder, Parkinson's dementia, Huntington's disease, Lewy body dementia, Alzheimer's disease, drug addiction, sleep disorders, or emotional blunting.

Citation Information

Patent Citations

  • A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

    WO2021001288A1

  • 3,4-dihydroisoquinolin-2(1h)-yl compounds

    CN105228985A

  • Tetrahydroisoquinoline derivatives

    CN108884050A